Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative …
Full GYRE analysis →
Competitive advantage assessment
Key strengths
Strong Interest Coverage & Conservative LeverageDebt serviceability is strong (score 0.83), with robust interest coverage.
Consistent Cash GenerationCash generation is strong and consistent (score 0.86).
Key risks
Revenue Volatility Signals Weak StickinessRevenue volatility is high (stability score 0.19), suggesting weak customer stickiness.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Gyre Therapeutics, Inc. ranks #49 of 713
scored companies in Biotechnology by moat score — the top 7%.
The widest moat in the group is Royalty Pharma plc (RPRX)
at 85/100.
Moat scores for companies ranked near GYRE in Biotechnology
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 80
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 60
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 57
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 76
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 74
· 15% of the moat score
Scale matters only when it converts into economics.
Gyre Therapeutics, Inc. (GYRE) scores 69 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #49 of 713 scored companies in Biotechnology, the top 7%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Cost Advantage (80/100) and its weakest is Capital Efficiency (57/100).
How does Gyre Therapeutics, Inc. compare with other Biotechnology companies?
Gyre Therapeutics, Inc. ranks #49 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are ImmuCell Corporation (ICCC) at 69 just above it and Amicus Therapeutics, Inc. (FOLD) at 68 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.
Why is Gyre Therapeutics, Inc. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Gyre Therapeutics, Inc.?
The Corporate Default template measures 6 defenses, and GYRE scores: Pricing Power (67), Cost Advantage (80), Customer Stickiness (60), Capital Efficiency (57), Resilience (76), Scale & Market Position (74). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.